Region
Featured experience
Guotai Junan merger with Haitong and concurrent placement of shares
We advised Guotai Junan Securities on the transaction, creating the largest securities company in China
Chagee $411.2 million IPO
We advised Chagee on its IPO and Nasdaq listing
Tencent €1.16 billion investment in new Ubisoft subsidiary
We are advising Tencent on the transaction
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Total victory in securities class actions related to COVID-19 pandemic
We secured dismissals of state and federal securities cases on behalf of Chinese audio platform Lizhi
InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Tencent Music Entertainment Group secondary listing
We advised Tencent Music Entertainment Group on its secondary listing by way of introduction on the HKEX
Interra Acquisition HK$1 billion IPO
We advised the SPAC on its IPO and HKEX listing
Tencent €300 million investment in Ubisoft
We are advising Tencent on the transaction
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Red Star Macalline Group $249.7 million credit enhanced bonds offering
We advised the issuer on the credit enhanced bonds offering
Esco Aster spinoff transactions
We are advising Esco Lifesciences on the spinoff
InSilico Medicine $35 million Series D2 financing
We are advising InSilico Medicine on the financing
Taibang Biologic Group $300 million equity raising
We are advising Taibang Biologic Group in connection with its equity raising by a group of investors